HALOZYME THERAPEUTICS INC

Form 4

December 04, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

OMB APPROVAL

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Lim Jonathan E

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

HALOZYME THERAPEUTICS INC [HALO]

(Check all applicable)

(Last)

C/O HALOZYME

(First)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

_X__ Director X_ Officer (give title

10% Owner Other (specify

11/30/2007

below)

President, CEO

THERAPEUTICS, INC., 11388 SORRENTO VALLEY ROAD

(Street)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

SAN DIEGO, CA 92121

(City)	(State)	Zip) Table	e I - Non-D	erivative S	Securit	ies Acq	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securities Acon(A) or Disposed (Instr. 3, 4 and 5) (A) or		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/30/2007		Code V M(1)	Amount 20,000	(D)	Price \$ 0.39	720,000	D	
Common Stock	11/30/2007		S <u>(1)</u>	2,568	D	\$ 8.31	717,432	D	
Common Stock	11/30/2007		S(1)	2,132	D	\$ 8.3	715,300	D	
Common Stock	11/30/2007		S <u>(1)</u>	100	D	\$ 8.29	715,200	D	
	11/30/2007		S(1)	400	D		714,800	D	

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock					\$ 8.27		
Common Stock	11/30/2007	S <u>(1)</u>	300	D	\$ 8.26	714,500	D
Common Stock	11/30/2007	S <u>(1)</u>	5,100	D	\$ 8.25	709,400	D
Common Stock	11/30/2007	S <u>(1)</u>	1,600	D	\$ 8.23	707,800	D
Common Stock	11/30/2007	S <u>(1)</u>	3,360	D	\$ 8.21	704,440	D
Common Stock	11/30/2007	S <u>(1)</u>	1,440	D	\$ 8.2	703,000	D
Common Stock	11/30/2007	S <u>(1)</u>	298	D	\$ 8.19	702,702	D
Common Stock	11/30/2007	S <u>(1)</u>	1,200	D	\$ 8.18	701,502	D
Common Stock	11/30/2007	S <u>(1)</u>	602	D	\$ 8.17	700,900	D
Common Stock	11/30/2007	S <u>(1)</u>	800	D	\$ 8.16	700,100	D
Common Stock	11/30/2007	S(1)	100	D	\$ 8.06	700,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of conDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase	\$ 0.39	11/30/2007		M(1)		20,000	11/11/2003	11/11/2013	Common Stock	20,000

SEC 1474

(9-02)

Common Stock

Reporting Owners

Reporting Owner Name / Address Relationships

X

Director 10% Owner Officer Other

Lim Jonathan E C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121

President, CEO

Signatures

James E. Cartoni, Attorney-in-fact for Jonathan E. Lim

12/04/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3